IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
LyGDI is a Promising Biomarker for Ovarian Cancer
Zhen, Hongying2; Yang, Shaomin3; Wu, Hounan4; Wang, Shuling2; Lv, Jingqiao5; Ma, Lijun6; Zhang, Xiaowei1
关键词Lygdi Ovarian Cancer Serum Tumor Marker
刊名INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
2010-04-01
DOI10.1111/IGC.0b013e3181d0b02d
20期:3页:316-322
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Obstetrics & Gynecology
资助者National Science Foundation of China ; National Science Foundation of China
研究领域[WOS]Oncology ; Obstetrics & Gynecology
关键词[WOS]GENE-EXPRESSION PROFILES ; LYMPH-NODE METASTASIS ; CDNA MICROARRAY ; BREAST-CANCER ; RHO-GTPASES ; PROTEINS ; PROGRESSION ; RHOGDI2
英文摘要

Introduction: LyGDI is an inhibitor of Rho protein activation by blocking its transformation between guanosine 5′-diphosphate- and guanosine 5′-triphosphate-bound states. The aim of this study was to investigate the usefulness of LyGDI as a biomarker for the detection of ovarian cancer, and its specificity and sensitivity were compared with those of cancer antigen 125 (CA125).

Methods: The serum levels of LyGDI were determined by enzyme-linked immunosorbent assay in 42 patients with ovarian disease, including 30 ovarian cancers and 12 benign ovarian lesions, and 76 healthy controls. The expression of LyGDI was also evaluated by immunohistochemical staining in resected ovarian tissues of these patients.

Results: The serum LyGDI level of cancers was significantly greater than those of the benign and healthy groups (P = 0.002 and P < 0.0001, respectively), whereas no difference was observed between the benign and control groups (P = 0.889). Based upon receiver operating characteristic curve analysis, LyGDI levels were able to distinguish ovarian cancer from benign ovarian disease (P = 0.0001) and healthy control (P G 0.0001; areas under the receiver operating characteristic curves, 0.876 and 0.833, respectively). For ovarian cancers, 83.3% (25/30) or 80.0% (24/30) was identified by serum LyGDI (>= 1.5 ng/mL) alone or by CA125 (>35 U/mL) alone. It is of particular importance to note that all cancer patients were identified by use of both markers, and the specificity was 83.3% for the benign group. Moreover, in early-stage cancers, 88.9% (8/9) had elevated serum LyGDI levels as compared with 44.4% (4/9) elevation of CA125 levels (P = 0.125). Immunohistochemical staining confirmed the expression of LyGDI on cancerous epithelial cells other than benign ovarian epithelium.

Conclusions: These results suggest that LyGDI has significant potential as a marker for detection of ovarian cancer in the patients with ovarian enlargement, including detection of early-stage cancers.

语种英语
所属项目编号39970763 ; 30471807
资助者National Science Foundation of China ; National Science Foundation of China
WOS记录号WOS:000276899900001
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54251
专题北京大学第三临床医学院
作者单位1.Peking Univ, Hosp 3, Dept Obstet & Gynecol, Beijing 100191, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Cell Biol, Beijing 100191, Peoples R China
3.Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100191, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Anal Ctr, Beijing 100191, Peoples R China
5.Peking Univ, Hosp 3, Dept Stat Anal, Beijing 100191, Peoples R China
6.Shanghai Jiao Tong Univ, Dept Oncol, Renji Hosp, Shanghai 200030, Peoples R China
推荐引用方式
GB/T 7714
Zhen, Hongying,Yang, Shaomin,Wu, Hounan,et al. LyGDI is a Promising Biomarker for Ovarian Cancer[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,2010,20(3):316-322.
APA Zhen, Hongying.,Yang, Shaomin.,Wu, Hounan.,Wang, Shuling.,Lv, Jingqiao.,...&Zhang, Xiaowei.(2010).LyGDI is a Promising Biomarker for Ovarian Cancer.INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER,20(3),316-322.
MLA Zhen, Hongying,et al."LyGDI is a Promising Biomarker for Ovarian Cancer".INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 20.3(2010):316-322.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhen, Hongying]的文章
[Yang, Shaomin]的文章
[Wu, Hounan]的文章
百度学术
百度学术中相似的文章
[Zhen, Hongying]的文章
[Yang, Shaomin]的文章
[Wu, Hounan]的文章
必应学术
必应学术中相似的文章
[Zhen, Hongying]的文章
[Yang, Shaomin]的文章
[Wu, Hounan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。